Generic Risperdal to impact anti-psychotics.

Publication: UPI Health Business

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2005 United Press International

Byline: STEVE MITCHELL

WASHINGTON, Nov. 30 (UPI) -- Market analysts said Wednesday they expect Johnson and Johnson's schizophrenic drug paliperidone to do well, but the big shake-up will be when the company's other anti-psychotic, Risperdal, goes generic in a couple of years.

J&J filed a new drug application with the Food and Drug Administration for paliperidone extended-release tablets Wednesday.

However, Oppenheimer and Co. analyst Scott Henry told United Press International that the big event in the anti-psychotic field will be when Risperdal goes off-patent in 2007 or 2008.

"A good bulk...

Read the full article for free courtesy of your local library.